Capricor Therapeutics Faces Investor Lawsuit Deadline

Capricor Therapeutics, Inc. (NASDAQ: CAPR) is facing a class action lawsuit, with a lead plaintiff deadline set for September 28, 2026. The lawsuit concerns events following the company's second-quarter 2026 earnings release and conference call.

Hagens Berman, a law firm specializing in investor rights, has highlighted the developments related to the lawsuit. The firm indicated that the case involves alleged misrepresentations and omissions concerning the company's business and prospects, potentially misleading investors.

Details of the alleged misconduct are expected to be further clarified as the legal proceedings advance. Investors who purchased Capricor Therapeutics stock during the specified class period may be eligible to serve as lead plaintiff.

The company has not yet issued a detailed statement on the specific allegations. The deadline for potential lead plaintiffs to come forward is critical for the progression of the class action.